Important safety information
Estrogen and endometrial cancer. FDA-approved estradiol labels carry a boxed warning: there is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestogen to estrogen-only therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Tell your provider about any unusual vaginal bleeding right away.
On November 10, 2025, the FDA asked makers of menopausal hormone therapy to remove boxed warning language on cardiovascular disease, breast cancer and probable dementia, and to keep the endometrial cancer boxed warning for systemic estrogen-alone products. The estradiol label still describes increased risks of stroke and blood clots with estrogen-alone therapy, and lists breast cancer, ovarian cancer, gallbladder disease, high blood pressure and vision problems among serious, less common side effects.
Tell your provider if you have unusual vaginal bleeding, have or have had breast cancer or another estrogen-sensitive cancer, a stroke, heart attack, blood clots or a clotting disorder, or liver problems, and if you are pregnant or breastfeeding. Tell your provider about every medication and supplement you take, and before any surgery or bed rest.
Based on the FDA prescribing information for Divigel (estradiol gel), revised February 2026. Biest cream is compounded and has no FDA label. Compounded medications are not FDA approved, and the FDA does not review compounded drugs for safety, effectiveness or quality.